Sydney Lupkin
Stories
-
Science
Remdesivir Priced At More Than $3,100 For A Course Of Treatment
An experimental COVID-19 medicine that has been shown to shorten the time people with severe illness have to stay in the hospital finally has a price tag that's lower than some analysts expected.
-
Health
Questions About How Crash Program Is Picking Coronavirus Vaccines To Back
As Operation Warp Speed pushes to develop a COVID-19 vaccine in record time, the number of candidates is being narrowed. The factors guiding the decision about which projects to fund is unclear.
-
Health
Putting A Price On COVID-19 Treatment Remdesivir
Gilead Sciences has committed to donating the initial supply of the experimental antiviral drug. But executives said the company will need to make expanded production of the treatment sustainable.
-
Business
What Would It Take To Bring More Pharmaceutical Manufacturing Back To The U.S.?
Experts say it could be dangerous to rely on overseas production of medicine in a crisis, but the U.S. largely does. Rebuilding domestic capacity would take years and substantial investments.
-
Health
HHS To Help Companies Develop COVID-19 Vaccines
The Department of Health and Human Services outlined support for Moderna and Johnson & Johnson, as the companies work to develop coronavirus vaccines. Beefing up manufacturing capacity is a priority.
-
Health
FDA OKs Addition To Stockpile Of Malaria Drugs For COVID-19
Chloroquine and hydroxycloroquine got the Food and Drug Administration's go-ahead to be put in the nation's strategic storehouses. But the drugs haven't been approved to treat coronavirus patients.
-
Health
Gilead Declines 'Rare Disease' Status For Experimental Coronavirus Drug
By renouncing the special status, Gilead Sciences lets go of tax breaks, fee waivers and seven years without generic competition for remdesivir, its experimental COVID-19 treatment.
-
Health
Insurers Cover Fewer Drugs, Leaving Some Patients Struggling To Get Needed Treatments
A new report finds insurers are becoming more selective about which medications they'll cover. Patients and doctors have to work harder to get treatments approved.
-
Health
Insurers Are Covering Far Fewer Drugs Than They Once Were
New research indicates that insurers are covering far fewer drugs than they did a decade ago. The reduction in options can interrupt care and leave people with hard choices at the pharmacy counter.
-
Health
How Coronavirus Is Affecting The U.S. Pharmaceutical Supply
In China, drug manufacturers are getting back to work. But supply chain disruptions could still lead to drug shortages down the road.